Alethia Young
Stock Analyst at Cantor Fitzgerald
(4.68)
# 132
Out of 4,479 analysts
101
Total ratings
58.49%
Success rate
27.52%
Average return
Main Sectors:
36 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $25.22 | - | 4 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $1,044.66 | -18.63% | 7 | Oct 16, 2023 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | $46 | $14.65 | +213.99% | 4 | Sep 12, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $5.72 | +214.69% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $6.25 | +860.00% | 3 | Sep 7, 2023 | |
| LBPH Longboard Pharmaceuticals | Reiterates: Overweight | $16 | $30.74 | -47.95% | 5 | Aug 22, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.41 | +273.44% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $2.94 | +1,058.43% | 2 | Jul 6, 2023 | |
| NEXI NexImmune | Downgrades: Neutral | n/a | $2.48 | - | 2 | Nov 16, 2022 | |
| BIIB Biogen | Maintains: Neutral | n/a | $228.82 | - | 4 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $6.84 | +338.60% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | n/a | $2.79 | - | 1 | Jun 14, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | n/a | $473.78 | - | 3 | Jun 11, 2021 | |
| AKBA Akebia Therapeutics | Initiates: Overweight | n/a | $0.96 | - | 1 | Mar 8, 2021 | |
| FATE Fate Therapeutics | Maintains: Overweight | n/a | $3.22 | - | 1 | Feb 25, 2021 | |
| AMGN Amgen | Maintains: Overweight | n/a | $310.77 | - | 6 | Feb 3, 2021 | |
| BCYC Bicycle Therapeutics | Initiates: Overweight | n/a | $19.81 | - | 1 | Oct 12, 2020 | |
| GILD Gilead Sciences | Maintains: Overweight | n/a | $68.40 | - | 2 | Aug 19, 2020 | |
| TGTX TG Therapeutics | Maintains: Overweight | n/a | $18.31 | - | 1 | May 6, 2020 | |
| MRNS Marinus Pharmaceuticals | Reiterates: Overweight | n/a | $1.19 | - | 1 | May 5, 2020 | |
| ASND Ascendis Pharma | Reiterates: Overweight | n/a | $136.27 | - | 5 | Apr 20, 2020 | |
| PTCT PTC Therapeutics | Reiterates: Overweight | n/a | $30.39 | - | 3 | Apr 8, 2020 | |
| PACB Pacific Biosciences of California | Assumes: Overweight | n/a | $1.28 | - | 1 | Mar 9, 2020 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Overweight | n/a | $5.43 | - | 1 | Mar 6, 2020 | |
| SRPT Sarepta Therapeutics | Reiterates: Overweight | n/a | $154.20 | - | 7 | Feb 27, 2020 | |
| AGIO Agios Pharmaceuticals | Reiterates: Overweight | n/a | $42.05 | - | 4 | Feb 14, 2020 | |
| INCY Incyte | Maintains: Neutral | n/a | $59.02 | - | 2 | Jan 3, 2020 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $23.94 | - | 2 | Jul 19, 2018 | |
| MESO Mesoblast | Downgrades: Underperform | n/a | $6.45 | - | 3 | Mar 22, 2018 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | n/a | $247.61 | - | 3 | Mar 13, 2018 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | n/a | $82.22 | - | 2 | Mar 2, 2018 | |
| PBYI Puma Biotechnology | Maintains: Outperform | n/a | $3.10 | - | 4 | Jan 24, 2018 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | n/a | $22.15 | - | 1 | Nov 3, 2017 | |
| DRI Darden Restaurants | Maintains: Neutral | n/a | $146.77 | - | 1 | Sep 27, 2017 | |
| UTHR United Therapeutics | Initiates: Underperform | n/a | $317.05 | - | 1 | Mar 16, 2017 | |
| ACIU AC Immune | Initiates: Outperform | n/a | $3.87 | - | 1 | Oct 18, 2016 |
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $25.22
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $1,044.66
Upside: -18.63%
Arcus Biosciences
Sep 12, 2023
Reiterates: Overweight
Price Target: $46
Current: $14.65
Upside: +213.99%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $5.72
Upside: +214.69%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $6.25
Upside: +860.00%
Longboard Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $30.74
Upside: -47.95%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.41
Upside: +273.44%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $2.94
Upside: +1,058.43%
NexImmune
Nov 16, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.48
Upside: -
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: n/a
Current: $228.82
Upside: -
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $6.84
Upside: +338.60%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: n/a
Current: $2.79
Upside: -
Vertex Pharmaceuticals
Jun 11, 2021
Maintains: Overweight
Price Target: n/a
Current: $473.78
Upside: -
Akebia Therapeutics
Mar 8, 2021
Initiates: Overweight
Price Target: n/a
Current: $0.96
Upside: -
Fate Therapeutics
Feb 25, 2021
Maintains: Overweight
Price Target: n/a
Current: $3.22
Upside: -
Amgen
Feb 3, 2021
Maintains: Overweight
Price Target: n/a
Current: $310.77
Upside: -
Bicycle Therapeutics
Oct 12, 2020
Initiates: Overweight
Price Target: n/a
Current: $19.81
Upside: -
Gilead Sciences
Aug 19, 2020
Maintains: Overweight
Price Target: n/a
Current: $68.40
Upside: -
TG Therapeutics
May 6, 2020
Maintains: Overweight
Price Target: n/a
Current: $18.31
Upside: -
Marinus Pharmaceuticals
May 5, 2020
Reiterates: Overweight
Price Target: n/a
Current: $1.19
Upside: -
Ascendis Pharma
Apr 20, 2020
Reiterates: Overweight
Price Target: n/a
Current: $136.27
Upside: -
PTC Therapeutics
Apr 8, 2020
Reiterates: Overweight
Price Target: n/a
Current: $30.39
Upside: -
Pacific Biosciences of California
Mar 9, 2020
Assumes: Overweight
Price Target: n/a
Current: $1.28
Upside: -
Aurinia Pharmaceuticals
Mar 6, 2020
Maintains: Overweight
Price Target: n/a
Current: $5.43
Upside: -
Sarepta Therapeutics
Feb 27, 2020
Reiterates: Overweight
Price Target: n/a
Current: $154.20
Upside: -
Agios Pharmaceuticals
Feb 14, 2020
Reiterates: Overweight
Price Target: n/a
Current: $42.05
Upside: -
Incyte
Jan 3, 2020
Maintains: Neutral
Price Target: n/a
Current: $59.02
Upside: -
AnaptysBio
Jul 19, 2018
Initiates: Outperform
Price Target: n/a
Current: $23.94
Upside: -
Mesoblast
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $6.45
Upside: -
Alnylam Pharmaceuticals
Mar 13, 2018
Maintains: Outperform
Price Target: n/a
Current: $247.61
Upside: -
BioMarin Pharmaceutical
Mar 2, 2018
Maintains: Outperform
Price Target: n/a
Current: $82.22
Upside: -
Puma Biotechnology
Jan 24, 2018
Maintains: Outperform
Price Target: n/a
Current: $3.10
Upside: -
Intellia Therapeutics
Nov 3, 2017
Maintains: Outperform
Price Target: n/a
Current: $22.15
Upside: -
Darden Restaurants
Sep 27, 2017
Maintains: Neutral
Price Target: n/a
Current: $146.77
Upside: -
United Therapeutics
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $317.05
Upside: -
AC Immune
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $3.87
Upside: -